Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
13,050
0.00 (0.00%)
At close: Oct 31, 2025
KRX:007570 Revenue
Ilyang Pharmaceutical Co.,Ltd had revenue of 62.70B KRW in the quarter ending June 30, 2025, with 7.24% growth. This brings the company's revenue in the last twelve months to 276.35B, up 26.66% year-over-year. In the year 2024, Ilyang Pharmaceutical Co.,Ltd had annual revenue of 268.86B with 0.82% growth.
Revenue (ttm)
276.35B
Revenue Growth
+26.66%
P/S Ratio
0.85
Revenue / Employee
414.94M
Employees
666
Market Cap
233.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 268.86B | 2.19B | 0.82% |
| Dec 31, 2023 | 266.67B | 18.90B | 7.63% |
| Dec 31, 2022 | 247.77B | 5.26B | 2.17% |
| Dec 31, 2021 | 242.51B | -100.82B | -29.36% |
| Dec 31, 2020 | 343.33B | 18.76B | 5.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |